Previous successful proposals
To date, four studies have been funded as a consequence of applications to the Inflammatory Arthritis CSG. The funded studies are:
- ORBIT: Optimal treatment of RA patients requiring Biologic therapy.
Duncan Porter and colleagues. A head-to-head comparison of rituximab and anti-TNF as first biologic therapy. This trial includes a pilot sub-study: Optimising the therapeutic utility of biologic agents using a synovial pathotype (OPUS), from the “Pathobiology of Early Arthritis Cohort” (PEAC). (Pitzalis, McInnes et al). This study asks whether a baseline synovial biopsy can inform the optimal therapeutic algorithm for an individual patient commencing biologic therapy.
- Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A Proof Of Principle And Exploratory Trial. Prof DL Scott. This study addresses whether it is possible to taper therapy in the established RA patient who is in remission on anti-TNF therapy.
- Development of the Rheumatoid Arthritis Patient Priorities for Pharmacological Interventions (RAPP-PI) outcome measures. (Pilot study, PI Dr T Sanderson, University of the West of England).
- Work Rehabilitation in Inflammatory Arthritis. Effectiveness and cost effectiveness of an occupational therapy (OT) job retention intervention: a randomised controlled trial. (Pilot study, PI Dr A Hammond, Salford University).